Aspira Women's Health (AWH) Competitors

iBio (NYSE:IBIO) and Aspira Women's Health (NASDAQ:AWH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings, profitability and community ranking.

Which has higher valuation and earnings, IBIO or AWH?

Aspira Women's Health has higher revenue and earnings than iBio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$375K	25.80	-$24.91M	N/A	N/A
Aspira Women's Health	$9.18M	0.25	-$16.69M	-$0.98	-0.08

Is IBIO or AWH more profitable?

iBio has a net margin of 0.00% compared to Aspira Women's Health's net margin of -165.07%. Aspira Women's Health's return on equity of 0.00% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-73.15%	-45.51%
Aspira Women's Health	-165.07%	N/A	-267.23%

Does the media favor IBIO or AWH?

In the previous week, Aspira Women's Health had 3 more articles in the media than iBio. MarketBeat recorded 3 mentions for Aspira Women's Health and 0 mentions for iBio. iBio's average media sentiment score of 0.72 beat Aspira Women's Health's score of 0.48 indicating that iBio is being referred to more favorably in the media.

Company	Overall Sentiment
iBio	Positive
Aspira Women's Health	Neutral

Which has more risk and volatility, IBIO or AWH?

iBio has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Aspira Women's Health has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.

Does the MarketBeat Community favor IBIO or AWH?

Aspira Women's Health received 11 more outperform votes than iBio when rated by MarketBeat users. However, 37.50% of users gave iBio an outperform vote while only 17.07% of users gave Aspira Women's Health an outperform vote.

Company	Underperform	Outperform
iBio	Outperform Votes 3 37.50%	Underperform Votes 5 62.50%
Aspira Women's Health	Outperform Votes 14 17.07%	Underperform Votes 68 82.93%

Do analysts prefer IBIO or AWH?

iBio presently has a consensus price target of $4.30, suggesting a potential upside of 338.82%. Aspira Women's Health has a consensus price target of $5.50, suggesting a potential upside of 7,024.35%. Given Aspira Women's Health's higher possible upside, analysts plainly believe Aspira Women's Health is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aspira Women's Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals & insiders have more ownership in IBIO or AWH?

7.9% of iBio shares are held by institutional investors. Comparatively, 12.2% of Aspira Women's Health shares are held by institutional investors. 0.6% of iBio shares are held by company insiders. Comparatively, 4.3% of Aspira Women's Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Aspira Women's Health beats iBio on 9 of the 15 factors compared between the two stocks.